Cantor Fitzgerald Predicts Higher Earnings for Immunocore

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Immunocore in a research report issued on Thursday, February 27th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($1.42) for the year, up from their previous forecast of ($2.33). The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share.

A number of other analysts also recently commented on IMCR. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, February 27th. Finally, Mizuho cut shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore currently has a consensus rating of "Moderate Buy" and an average target price of $65.64.

Immunocore Price Performance

NASDAQ:IMCR traded up $0.56 during midday trading on Monday, hitting $30.81. 308,960 shares of the stock were exchanged, compared to its average volume of 228,980. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -32.43 and a beta of 0.79. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a one year low of $27.69 and a one year high of $66.00. The business has a 50-day moving average price of $30.15 and a two-hundred day moving average price of $31.69.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock worth $219,430,000 after purchasing an additional 668,382 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunocore by 3.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after purchasing an additional 200,373 shares in the last quarter. FMR LLC boosted its position in shares of Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company's stock worth $150,546,000 after buying an additional 23,436 shares during the period. Primecap Management Co. CA grew its holdings in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after buying an additional 196,530 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after buying an additional 29,832 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.